Table 2.
Patient characteristics, overall and by country.
| Characteristic | Overall (N=807) | UK (n=199) | Spain (n=203) | Germany (n=204) | France (n=201) | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| n | % | n | % | n | % | n | % | n | % | |
| Sex | ||||||||||
| Male | 475 | 58.9 | 126 | 63.3 | 123 | 60.6 | 130 | 63.7 | 96 | 47.8 |
| Female | 332 | 41.1 | 73 | 36.7 | 80 | 39.4 | 74 | 36.3 | 105 | 52.2 |
|
| ||||||||||
| Age at advanced diagnosis (years) | ||||||||||
| Mean (SD) | 57.1 | 12.3 | 56.5 | 12.4 | 56.6 | 13.1 | 57.4 | 11.0 | 57.9 | 12.6 |
| Range (minimum, maximum) | 21 | 90 | 21 | 90 | 21 | 85 | 28 | 77 | 22 | 84 |
|
| ||||||||||
| Ethnicity a | ||||||||||
| White/Caucasian | 562 | 92.7 | 178 | 89.5 | 201 | 99.0 | 183 | 89.7 | — | — |
| African/Black | 14 | 2.3 | 10 | 5.0 | 0 | 0 | 4 | 2.0 | — | — |
| Asian or Pacific Islander | 14 | 2.3 | 6 | 3.0 | 0 | 0 | 8 | 3.9 | — | — |
| Middle eastern | 8 | 1.3 | 2 | 1.0 | 2 | 1.0 | 4 | 2.0 | — | — |
| Indian subcontinent | 8 | 1.3 | 3 | 1.5 | 0 | 0 | 5 | 2.5 | — | — |
|
| ||||||||||
| Histologic category | ||||||||||
| Leiomyosarcoma | 229 | 28.4 | 61 | 30.7 | 45 | 22.2 | 66 | 32.4 | 57 | 28.4 |
| Others/NOS | 183 | 22.7 | 40 | 20.1 | 35 | 17.2 | 43 | 21.1 | 65 | 32.3 |
| Fibroblastic/myofibroblastic sarcoma | 78 | 9.7 | 24 | 12.1 | 18 | 8.9 | 20 | 9.8 | 16 | 8.0 |
| Liposarcoma | 105 | 13.0 | 14 | 7.0 | 44 | 21.7 | 22 | 10.8 | 25 | 12.4 |
| Vascular sarcoma | 79 | 9.8 | 16 | 8.0 | 25 | 12.3 | 17 | 8.3 | 21 | 10.4 |
| Rhabdomyosarcoma | 86 | 10.7 | 33 | 16.6 | 20 | 9.9 | 21 | 10.3 | 12 | 6.0 |
| Synovial sarcoma | 47 | 5.8 | 11 | 5.5 | 16 | 7.9 | 15 | 7.4 | 5 | 2.5 |
|
| ||||||||||
| Stage of the disease at initial diagnosis | ||||||||||
| 1A | 1 | 0.1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0.5 |
| 1B | 20 | 2.5 | 6 | 3.0 | 5 | 2.5 | 6 | 2.9 | 3 | 1.5 |
| IIA | 37 | 4.6 | 7 | 3.5 | 9 | 4.4 | 3 | 1.5 | 18 | 9.0 |
| IIB | 87 | 10.8 | 12 | 6.0 | 30 | 14.8 | 13 | 6.4 | 32 | 15.9 |
| III (with no regional lymph node metastasis) | 44 | 5.5 | 6 | 3.0 | 10 | 4.9 | 9 | 4.4 | 19 | 9.5 |
| III (with regional lymph node metastasis) | 61 | 7.6 | 11 | 5.5 | 10 | 4.9 | 16 | 7.8 | 24 | 11.9 |
| IV | 557 | 69.0 | 157 | 78.9 | 139 | 68.5 | 157 | 77.0 | 104 | 51.7 |
| Number of patients where initial diagnosis was not an advanced stageb | 188 | 23.3 | 25 | 12.6 | 54 | 26.6 | 27 | 13.2 | 82 | 40.8 |
|
| ||||||||||
| CCI score at advanced diagnosis c | ||||||||||
| Mean (SD) | 1.0 | 1.1 | 1.0 | 1.1 | 1.0 | 1.0 | 1.0 | 1.1 | 0.8 | 1.2 |
| Range (minimum, maximum) | 0 | 6 | 0 | 5 | 0 | 4 | 0 | 6 | 0 | 6 |
|
| ||||||||||
| Most common CCI conditions at advanced diagnosis c | ||||||||||
| Depression | 104 | 12.9 | 23 | 11.6 | 33 | 16.3 | 29 | 14.2 | 19 | 9.5 |
| Diabetes without complications | 102 | 12.6 | 20 | 10.1 | 40 | 19.7 | 30 | 14.7 | 12 | 6.0 |
| Hypertension | 259 | 32.1 | 64 | 32.2 | 63 | 31.0 | 74 | 36.3 | 58 | 28.9 |
|
| ||||||||||
| Anatomic location of primary tumor | ||||||||||
| Axilla | 12 | 1.5 | 5 | 2.5 | 2 | 1.0 | 3 | 1.5 | 2 | 1.0 |
| Breast | 20 | 2.5 | 3 | 1.5 | 7 | 3.5 | 4 | 2.0 | 6 | 3.0 |
| Lower extremity | 187 | 23.2 | 42 | 21.1 | 53 | 26.1 | 53 | 26.0 | 39 | 19.4 |
| Upper extremity | 97 | 12.0 | 27 | 13.6 | 28 | 13.8 | 28 | 13.7 | 14 | 7.0 |
| Head or neck | 48 | 6.0 | 15 | 7.5 | 12 | 5.9 | 14 | 6.9 | 7 | 3.5 |
| Gastrointestinal | 38 | 4.7 | 16 | 8.0 | 5 | 2.5 | 12 | 5.9 | 5 | 2.5 |
| Genitourinary | 13 | 1.6 | 4 | 2.0 | 3 | 1.5 | 2 | 1.0 | 4 | 2.0 |
| Gynecologic (other than uterus) | 9 | 1.1 | 1 | 0.5 | 2 | 1.0 | 3 | 1.5 | 3 | 1.5 |
| Mediastinum, lung, or pleura | 26 | 3.2 | 4 | 2.0 | 9 | 4.4 | 7 | 3.4 | 6 | 3.0 |
| Pelvis (nonvisceral) | 65 | 8.1 | 23 | 11.6 | 13 | 6.4 | 17 | 8.3 | 12 | 6.0 |
| Retroperitoneal | 124 | 15.4 | 24 | 12.1 | 33 | 16.3 | 27 | 13.2 | 40 | 19.9 |
| Trunk | 67 | 8.3 | 16 | 8.0 | 11 | 5.4 | 18 | 8.8 | 22 | 11.0 |
| Uterus | 85 | 10.5 | 13 | 6.5 | 22 | 10.8 | 16 | 7.8 | 34 | 16.9 |
| Unknown | 13 | 1.6 | 6 | 3.0 | 1 | 0.5 | 0 | 0 | 6 | 3.0 |
|
| ||||||||||
| Site of metastasis among patients with distant metastasis | ||||||||||
| Bone | 105 | 15.9 | 26 | 14.4 | 30 | 18.1 | 28 | 15.6 | 21 | 15.6 |
| Brain | 16 | 2.4 | 3 | 1.7 | 8 | 4.8 | 2 | 1.1 | 3 | 2.2 |
| Distant lymph nodes | 161 | 24.4 | 56 | 31.1 | 36 | 21.7 | 51 | 28.3 | 18 | 13.3 |
| Exoskeletal | 28 | 4.2 | 10 | 5.6 | 6 | 3.6 | 9 | 5.0 | 3 | 2.2 |
| Liver | 187 | 28.3 | 58 | 32.2 | 42 | 25.3 | 56 | 31.1 | 31 | 23.0 |
| Lung | 468 | 70.8 | 112 | 62.2 | 125 | 75.3 | 125 | 69.4 | 106 | 78.5 |
| Mediastinum | 38 | 5.8 | 11 | 6.1 | 11 | 6.6 | 8 | 4.4 | 8 | 5.9 |
| Pericardium | 9 | 1.4 | 2 | 1.1 | 3 | 1.8 | 3 | 1.7 | 1 | 0.7 |
| Peritoneum | 98 | 14.8 | 32 | 17.8 | 15 | 9.0 | 30 | 16.7 | 21 | 15.6 |
| Pleura | 42 | 6.4 | 8 | 4.4 | 12 | 7.2 | 9 | 5.0 | 13 | 9.6 |
| Retroperitoneum | 18 | 2.7 | 5 | 2.8 | 5 | 3.0 | 5 | 2.8 | 3 | 2.2 |
| Others | 5 | 0.8 | 1 | 0.6 | 0 | 0 | 0 | 0 | 4 | 3.0 |
| Unknown | 2 | 0.3 | 1 | 0.6 | 1 | 0.6 | 0 | 0 | 0 | 0 |
|
| ||||||||||
| ECOG PS at advanced diagnosis | ||||||||||
| PS 0 | 84 | 10.4 | 15 | 7.5 | 23 | 11.3 | 18 | 8.8 | 28 | 13.9 |
| PS 1 | 474 | 58.7 | 162 | 81.4 | 86 | 42.4 | 144 | 70.6 | 82 | 40.8 |
| PS ≥ 2 | 249 | 30.9 | 22 | 11.1 | 94 | 46.3 | 42 | 20.6 | 91 | 45.3 |
CCI: Charlson Comorbidity Index; ECOG: Eastern Cooperative Oncology Group; NOS: not otherwise specified; PS: performance status; SD: standard deviation; STS: soft tissue sarcoma; UK: United Kingdom; anot collected in France; bpatients with stage I, II, or III at initial diagnosis and with time from initial to advanced diagnosis greater than zero; cbecause the objective of the CCI score was to evaluate underlying comorbidity burden independent of STS, cancer was excluded from the CCI calculation for this study.